CN112638865A - 药物共晶体及其制备方法 - Google Patents

药物共晶体及其制备方法 Download PDF

Info

Publication number
CN112638865A
CN112638865A CN201980057194.XA CN201980057194A CN112638865A CN 112638865 A CN112638865 A CN 112638865A CN 201980057194 A CN201980057194 A CN 201980057194A CN 112638865 A CN112638865 A CN 112638865A
Authority
CN
China
Prior art keywords
crystal
ray powder
powder diffraction
diffraction pattern
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980057194.XA
Other languages
English (en)
Other versions
CN112638865B (zh
Inventor
张�杰
陈勇
罗忠华
黄芳芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN112638865A publication Critical patent/CN112638865A/zh
Application granted granted Critical
Publication of CN112638865B publication Critical patent/CN112638865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明主要提供了药物共晶体及其制备方法，属于医药化工技术领域。该药物共晶体由Ralinepag和异烟碱形成，具有稳定性良好，溶解度大，适于制备药用组合物等优势。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201980057194.XA 2018-09-06 2019-08-14 药物共晶体及其制备方法 Active CN112638865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811037836 2018-09-06
CN2018110378363 2018-09-06
PCT/CN2019/100468 WO2020048299A1 (zh) 2018-09-06 2019-08-14 药物共晶体及其制备方法

Publications (2)

Publication Number Publication Date
CN112638865A true CN112638865A (zh) 2021-04-09
CN112638865B CN112638865B (zh) 2022-07-26

Family

ID=69722993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980057194.XA Active CN112638865B (zh) 2018-09-06 2019-08-14 药物共晶体及其制备方法

Country Status (2)

Country Link
CN (1) CN112638865B (zh)
WO (1) WO2020048299A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023222747A1 (en) * 2022-02-15 2024-08-22 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011037613A1 (en) * 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
CN102036659A (zh) * 2008-03-18 2011-04-27 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
CN102503886A (zh) * 2011-10-11 2012-06-20 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN106986868A (zh) * 2016-01-21 2017-07-28 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
CN107445942A (zh) * 2016-05-31 2017-12-08 广东东阳光药业有限公司 右兰索拉唑共晶及其制备方法
WO2018089804A1 (en) * 2016-11-10 2018-05-17 Arena Pharmaceuticals, Inc. Methods of treating pah with combinations of ralinepag and other agents
CN110903219A (zh) * 2018-09-18 2020-03-24 广东东阳光药业有限公司 酰胺衍生物的盐及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036659A (zh) * 2008-03-18 2011-04-27 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
WO2011037613A1 (en) * 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
CN102503886A (zh) * 2011-10-11 2012-06-20 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN106986868A (zh) * 2016-01-21 2017-07-28 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
CN107445942A (zh) * 2016-05-31 2017-12-08 广东东阳光药业有限公司 右兰索拉唑共晶及其制备方法
WO2018089804A1 (en) * 2016-11-10 2018-05-17 Arena Pharmaceuticals, Inc. Methods of treating pah with combinations of ralinepag and other agents
CN110903219A (zh) * 2018-09-18 2020-03-24 广东东阳光药业有限公司 酰胺衍生物的盐及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THUY-ANH TRAN, ET AL.,: ""Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension"", 《J. MED. CHEM.,》 *
陈嘉媚等: ""超分子化学在药物共晶中的应用"", 《高等学校化学学报》 *

Also Published As

Publication number Publication date
CN112638865B (zh) 2022-07-26
WO2020048299A1 (zh) 2020-03-12

Similar Documents

Publication Publication Date Title
JP6483126B2 (ja) イブルチニブの結晶形態ｉ
CN106986868B (zh) 包含阿哌沙班的共晶体及其制备方法
WO2021129589A1 (zh) Kd-025的新晶型及其制备方法
CN116829144A (zh) 一种化合物的固体形式及其制备方法和用途
CN111377944A (zh) Baloxavir marboxil晶型及其制备方法
US20220169658A1 (en) Crystal form of gonadotropin releasing hormone antagonist, preparation method therefor, and use thereof
CN112638865B (zh) 药物共晶体及其制备方法
CN114728954B (zh) Tropifexor的新晶型及其制备方法
CN114478512A (zh) 一种酸的晶型及其制备方法
US10098859B2 (en) Cocrystals of p-coumaric acid
CN110903219A (zh) 酰胺衍生物的盐及其制备方法
JP2022511495A (ja) Ｍｃｌ－１阻害剤の新しい結晶形、その調製プロセス及びそれらを含有する医薬組成物
WO2022253234A1 (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
WO2021104021A1 (zh) Tropifexor的新晶型及其制备方法
CN114258395A (zh) 一种酯化合物的晶型及其制备方法
WO2017028762A1 (zh) 一种萘环化合物的晶型
CN113549011A (zh) 德度司他的共晶或盐及其制备方法和用途
WO2018086473A1 (zh) 阿普斯特共晶及其制备方法
WO2022048613A1 (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN114591211A (zh) 一种酰胺化合物的共晶及其制备方法
WO2020259366A1 (zh) 一种凝血因子XIa抑制剂的晶型及其制备方法
CN115246830A (zh) 一种酸的固体形式及其制备方法
CN114105867A (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN115197209A (zh) 一种酸的晶型及其制备方法
WO2024179558A1 (zh) Pirtobrutinib的晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 Songshan Hubei Industrial Park, Dongguan City, Guangdong Province

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.